NRAS and neoplasm: Our data strongly suggest that mutation screening should be extended beyond KRAS exon 2 to include KRAS exons 3 and 4, BRAF, and NRAS. These variants were associated with poor tumor responses and shorter PFS in mCRC patients with wild-type KRAS who were treated with the anti-EGFR agent cetuximab.